Corcept Therapeutics Incorporated

Healthcare · Biotechnology

116.20$ +1.9% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Corcept Therapeutics Incorporated (CORT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 889 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CORT
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	63	69	75	87	111	221	243	274	300	312	320	329	367	412	445	498	534	572	552	568	585	424	468	496	533	583	618	525	594	622	656	715	784	841	846	802	824	837	815	889
Current Assets	60	66	73	83	94	141	165	197	224	241	217	263	267	307	345	438	463	479	410	411	402	266	388	419	452	499	534	433	432	459	503	561	467	472	439	443	541	485	426	440
Cash	48	52	57	68	77	104	140	31	34	207	50	226	45	31	84	59	31	76	52	95	95	78	62	35	50	66	300	172	112	136	150	129	137	128	90	103	125	120	109	111
Cash & Short-Term Investments	48	52	57	68	77	104	140	160	195	207	187	226	232	276	307	405	429	441	373	370	361	224	346	370	396	432	465	363	355	368	411	473	380	383	323	342	422	372	338	308
Receivables	8.2	9.9	9.2	9.5	12	28	17	29	19	18	19	20	22	20	27	23	22	26	22	28	27	29	28	30	30	47	48	47	50	57	64	56	63	58	84	69	74	60	39	77
Inventory	2.3	2.3	6.7	6.3	5.5	8.4	7.8	4.9	5.4	16	5.0	18	5.5	5.4	5.1	4.9	4.8	4.9	4.9	4.7	5.0	5.0	5.1	5.4	6.0	6.1	6.4	6.9	7.5	7.7	7.2	8.4	8.1	12	14	12	12	13	13	13
Property, Plant & Equipment	0.1	0.2	0.3	0.5	0.6	0.5	0.6	0.6	0.5	0.7	0.9	1.2	1.2	1.1	0.9	0.6	1.3	1.7	1.5	2.9	1.2	1.0	0.7	2.3	0.8	1.8	0.5	0.4	0.5	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	32	27	26	20	24	30	28	31	40	36	34	31	33	41	36	44	44	48	42	46	45	48	60	54	60	82	88	103	132	115	108	118	145	161	163	166	192	189	177	183
Current Liabilities	32	27	16	16	24	30	28	31	40	36	34	31	32	39	34	42	43	47	41	45	45	48	57	49	53	72	79	93	122	105	97	101	126	141	143	145	172	166	149	154
Short-Term Debt	19	15	10	4.6	–	–	–	–	–	–	1.5	1.1	0.8	1.6	1.6	2.0	2.0	2.0	2.1	1.6	1.0	0.5	2.3	2.3	1.7	1.1	0.6	0.3	0.2	0.2	0.1	0.0	0.4	0.8	1.0	1.0	1.1	1.1	1.6	1.9
Accounts Payable	4.3	2.3	4.3	2.1	6.2	8.6	7.9	6.4	14	8.3	9.3	7.0	5.9	7.5	5.0	6.3	6.5	11	7.0	9.2	6.6	6.9	9.3	8.2	8.2	12	11	8.0	17	17	13	19	19	15	28	24	34	40	33	15
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	31	41	50	66	86	191	215	244	260	276	286	298	334	371	409	454	490	523	511	523	540	376	408	442	473	502	530	422	462	507	548	596	639	680	683	636	632	648	638	706
Retained Earnings	-327	-322	-318	-305	-291	-193	-176	-157	-140	-118	-99	-79	-53	-24	6.5	35	56	82	106	132	163	195	218	245	280	296	312	340	371	403	430	466	513	544	564	599	619	643	612	655
Shares Outstanding	116	113	121	123	126	127	128	128	126	125	124	122	122	123	122	123	124	127	130	127	125	122	115	115	117	116	115	110	111	111	110	111	114	118	120	120	119	120	104	118

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings